JNJ-77242113

Phase 3Small molecule

Johnson & Johnson

JNJ-77242113 is one of 12 small molecule programs targeting Plaque Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plaque PsoriasisActive, not recruiting

Generalized Pustular PsoriasisActive, not recruiting

Plaque PsoriasisPhase 3

Active, not recruiting

Generalized Pustular PsoriasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Plaque Psoriasis

#DrugCompanyPhaseTrials

Otezla

Amgen

Phase 3

4 2

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 3

JNJ-77242113

Johnson & Johnson

Phase 3

5 4

Envudeucitinib

AAlumis Inc

Phase 3

3 5

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 6

ESK-001

AAlumis Inc

Phase 2

3 7

ORKA-001

OOruka Therapeutics, Inc.

Phase 2

3 8

ZP9830

Zealand Pharma

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06095102

Q2 2027

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06095115

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06143878

Q3 2027

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06934226

Phase 3Active, not recruiting

Plaque Psoriasis

NCT06220604

Q4 2027

Phase 3Active, not recruiting

Generalized Pustular Psoriasis

NCT06295692

Clinical

Trials by Indication[1]

Plaque Psoriasis5 trials

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06220604·731 enrolled

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06095102·311 enrolled

77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06934226·752 enrolled

Show 2 more trials

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06095115·684 enrolled

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06143878·774 enrolled